GeNeuro SA Announces the End of the Debt Moratorium and the Commencement of Bankruptcy Proceedings

GENEVA, Switzerland--(BUSINESS WIRE)--Regulatory News:

GeNeuro SA (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance, in a ruling notified on January 28, 2026, considered there was no ground to extend the definitive debt moratorium and, as a result, has declared GeNeuro SA bankrupt.

As previously announced, GeNeuro SA had obtained on September 26, 2025, a definitive debt-restructuring moratorium of four months, expiring on January 27, 2026, to allow GeNeuro SA to further its efforts to evaluate all available options, including recapitalization, advancing and/or monetizing its therapeutic assets in development, and negotiating agreements with its creditors.

However, despite the scientific interest of the Company's clinical and preclinical programs in indications such as multiple sclerosis, amyotrophic lateral sclerosis, and long COVID, and despite the steps taken during the moratorium period, no recovery or restructuring solution could be finalized to ensure the Company's long-term viability. In this context, the Court decided not to extend the debt moratorium and to declare the Company bankrupt.

The Geneva Court of First Instance judgment will be published today in the Feuille d'Avis Officielle du canton de Genève and the Feuille Officielle Suisse du Commerce.

Any further information is now the responsibility of the Geneva Cantonal Bankruptcy Office. It should be noted that, under the rules applicable to bankruptcy proceedings, creditors take priority over shareholders. Given the amount of the Company's debts, it seems highly likely that shareholders will not be able to recover any proceeds from the liquidation.

Disclaimer
This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law..